Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC. (Q51326919)

3 April 2018

title

Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC. (English)

1 reference

3 April 2018

author

Matteo Landriscina

3

1 reference

3 April 2018

author name string

Angela Zupa

1

1 reference

3 April 2018

Giulia Vita

2

1 reference

3 April 2018

Luciana Possidente

4

1 reference

3 April 2018

Michele Aieta

5

1 reference

3 April 2018

Alfredo Tartarone

6

1 reference

3 April 2018

Giuseppina Improta

7

1 reference

3 April 2018

publication date

8 July 2012

1 reference

3 April 2018

published in

Medical Oncology

1 reference

3 April 2018

volume

29

1 reference

3 April 2018

issue

5

1 reference

3 April 2018

page(s)

3198-3201

1 reference

3 April 2018

https://scigraph.springernature.com/pub.10.1007/s12032-012-0304-y

exact match

0 references

cites work

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

Role of 3':5'-cyclic-AMP-dependent protein kinase in regulation of protein synthesis in reticulocyte lysates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0304-Y

Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status

21 January 2018

1 reference

12 December 2020

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

1 reference

12 December 2020

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

1 reference

12 December 2020

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

1 reference

12 December 2020

EGFR mutations as a predictive marker of cytotoxic chemotherapy

1 reference

12 December 2020

10.1007/S12032-012-0304-Y

Identifiers

DOI

1 reference

3 April 2018

1 reference

3 April 2018